Pre-exposure prophylaxis for HIV prevention: how to predict success
نویسندگان
چکیده
منابع مشابه
Pre-Exposure Prophylaxis for HIV Prevention.
c ase vignet tes The first patient, a 46-year-old sexually active man who has sex with men, presents for routine primary care. He lives in New York City and reports that he is in a long-term, stable, open relationship with a male partner and that he has had multiple recent sexual encounters with acquaintances. A recent HIV test was negative. He has seasonal allergies, for which he occasionally ...
متن کاملAdolescent pre-exposure prophylaxis for HIV prevention: current perspectives
Adolescents are a critical population that is disproportionately impacted by the HIV epidemic. More than 2 million adolescents between the age group of 10 and 19 years are living with HIV, and millions are at risk of infection. HIV risks are considerably higher among girls, especially in high-prevalence settings such as eastern and southern Africa. In addition to girls, there are other vulnerab...
متن کاملPre-exposure prophylaxis for HIV prevention in women: current perspectives
There are ~900,000 new HIV infections among women every year, representing nearly half of all new HIV infections globally. In the US, nearly one-fifth of all new HIV infections occur among women, and women from racial and ethnic minority communities experience disproportionately high rates of new HIV infections. Thus, there is a need to develop and implement effective HIV prevention strategies ...
متن کاملCDC promotes pre-exposure prophylaxis for HIV prevention.
The US Centers for Disease Control and Prevention (CDC) has issued guidance for the broad use of pre-exposure prophylaxis for HIV prevention—better known by the shorthand PrEP—which builds on interim guidance issued in 2012. Truvada is a single pill containing two commonly used HIV drugs, tenofovir and emtricitabine, and it is the only product that currently carries a label indication for PrEP,...
متن کاملPre-Exposure Prophylaxis for HIV Prevention: Safety Concerns
Available evidence supports the efficacy of pre-exposure prophylaxis (PrEP) in decreasing the incidence of human immunodeficiency virus (HIV) infection among high-risk individuals, especially when used in combination with other behavioural preventive methods. Safety concerns about PrEP present challenges in the implementation and use of PrEP. The aim of this review is to discuss safety concerns...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Lancet
سال: 2012
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(11)61852-7